MT

Molecular Therapy Oncology

Molecular Therapy Oncology is an international, online-only, open-access journal focusing on the development and testing of cancer therapies in pre-clinical and clinical settings. It provides a forum for biologic cancer therapies including viral, bacterial, cellular, and gene therapy, and also considers innovative approaches to cancer treatment and predictive biomarkers of response. Most accepted papers have translational relevance.

Looking to publish in Molecular Therapy Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Medicine, Research & Experimental, Oncology
Impact Factor 5.3
Quartile Q1
Open Access Type Open
eISSN 2950-3299
Invitation Only No
Cost Range Open access fee: $3,120 for members and $3,900 for non-members, plus VAT where applicable.

Submission Instructions

Molecular Therapy Oncology accepts the following article types. Click on an article type to view submission instructions.

Original Research Article

Cover Letter A cover letter on institutional letterhead is required. Cover letter must explain the conceptual advance and relevance to readers, disclose information relevant to handling or evaluation, declare financial conflicts of interest, and describe any related papers and how they relate to the submission.
Abstract An unstructured abstract is required. Abstract must be no more than 200 words. Abstract must be unstructured and presented as a single paragraph.
Manuscript Manuscript must be organized as abstract, introduction, results, discussion, materials & methods, data availability statement, acknowledgments, author contributions, declaration of interests statement, 5-10 keywords, references, tables, and a list of figure legends, with results and discussion in separate sections. Manuscript must include 5-10 keywords, an author contributions section, a separate Declaration of Interests section before the references, a declaration of generative AI and AI-assisted technologies in the writing process before the references when applicable, a graphical abstract, and an eTOC synopsis of 50 words or fewer in paragraph form.
References References must include only published or in-press works, be cited as superscript numbers in order of appearance after punctuation, be listed in numerical order, use PubMed journal abbreviations, and list the first ten authors followed by et al. when there are more than ten authors.
Figures & Tables No more than 8 display items, including figures and tables, may be included. For initial review, figures may be included after the tables in the manuscript file, and high-resolution figures must also be uploaded separately. Tables must be created as Word tables with informative titles above them, and figure legends must be provided in a list rather than on the high-resolution figure files.
Reformat to Molecular Therapy Oncology using Livewrite Premium

Review Article

Cover Letter A cover letter on institutional letterhead is required. Cover letter must explain the conceptual advance and relevance to readers, provide information relevant to handling and evaluation, and declare any financial conflicts of interest.
Abstract An abstract is required. Abstract must be unstructured and no more than 200 words. Abstract must be unstructured and presented as a single paragraph without headings.
Manuscript Manuscript must be organized as introduction, text, acknowledgments, author contributions, declaration of interest statement, 5-10 keywords, references, tables, and a list of figure legends. Manuscript must include a graphical abstract, an eTOC synopsis, 5-10 keywords, an author contributions section, a Declaration of Interests section, and a Declaration of Generative AI and AI-assisted technologies in the writing process section before the references if applicable.
References References must be cited as superscript numbers in order of appearance after punctuation, listed numerically, include only published or in-press works, use PubMed journal abbreviations, and list the first ten authors followed by et al. for references with more than ten authors.
Figures & Tables Review Article manuscripts may include no more than 8 display items total, including figures and tables. For initial review, figures may be included after the tables in the manuscript file, and high-resolution figure files must also be uploaded separately. Tables and figures must be numbered sequentially, tables must have titles above them, and figure legends must be provided as a separate list in the manuscript.
Reformat to Molecular Therapy Oncology using Livewrite Premium

Brief Report

Cover Letter A cover letter is required. Cover letter must explain the conceptual advance and relevance to readers, note information relevant to handling and evaluation, and declare any financial conflicts of interest.
Abstract An abstract is required. Abstract must be unstructured and no more than 200 words. Abstract must be unstructured and presented as a single paragraph without headings.
Manuscript Manuscript must not exceed 4,000 words, excluding disclosures and references. Manuscript must be organized as abstract, introduction, results, discussion, materials & methods, data availability statement, acknowledgments, author contributions, declaration of interest statement, 5-10 keywords, references, tables, and a list of figure legends. Manuscript must include a graphical abstract, 5-10 keywords, an author contributions section, a declaration of interest statement, and a Declaration of Generative AI and AI-assisted technologies in the writing process before the references if such tools were used.
References Reference list may include a maximum of 30 references. References must be cited as superscript numerals in order of appearance after punctuation, listed in numerical order, include only published or in-press works, use PubMed journal abbreviations, and list the first ten authors followed by et al. for works with more than ten authors.
Figures & Tables Manuscript may include no more than 3 display items in total, including figures and tables. For initial review, figures may be included after the tables in the manuscript file, and high-resolution figures must also be uploaded separately. Figures and tables must be numbered sequentially in Arabic numerals, tables must have titles above them, and the submission must include a list of figure legends.
Reformat to Molecular Therapy Oncology using Livewrite Premium

Letter To The Editor

Cover Letter A cover letter on institutional letterhead is required. Cover letter must explain the conceptual advance and relevance to readers, disclose financial conflicts of interest, and note information relevant to handling such as related work, time constraints, or competition.
Abstract Abstract requirement is not stated for this article type.
Manuscript Letter To The Editor manuscripts must not exceed 1200 words, excluding disclosures and references. Letter To The Editor manuscripts must not present unpublished data in support of the author's position. Manuscripts must include a declaration of generative AI and AI-assisted technologies in the writing process before the references if such tools were used.
References Letter To The Editor manuscripts may include a maximum of 10 references. References must be cited as superscript numerals in order of appearance, and the reference list must be numbered in that same order with more than ten authors shortened to the first ten followed by et al.
Figures & Tables Letter To The Editor manuscripts must not include display items.
Reformat to Molecular Therapy Oncology using Livewrite Premium

Recent Publications

Fit cells, fertile ground: Immunometabolic programming and bone marrow niche support in durable CAR T cell response in leukemia

Xiuli Wang, Lior Goldberg

10.1016/j.omton.2026.201222
View Publication

Cancer frenemy pathways: Inducing immunogenic cell death by exploiting apoptosis-interferon antagonism with oncolytic viruses

Vladimir Bozhdansky, Eran Bacharach, Marcelo Ehrlich

10.1016/j.omton.2026.201211
View Publication

Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations

Giulia Escobar, Marcela V. Maus

10.1016/j.omton.2026.201231
View Publication

Atorvastatin Pre-exposure in Hypercholesterolemia Remedies 27HC Mediated Dendritic Cell Dysfunctions in Triple-Negative Breast Cancer

Pritha Roy Choudhury, Mohona Chakravarti, Saurav Bera, Pooja Arora, Jasmine Sultana, Muqtada Ali Khan, Rushikesh Biradar, Aishwarya Guha, Sukanya Dhar, Indranil Ghosh, Nilanjan Ganguly, Aarti Lasure, Priyanka Kashyap, Juhina Das, Biswajit Mandal, Prodipto Das, Anirban Sarkar, Dipak Datta, Sukhendu Nandi, Neyaz Alam, Rathindranath Baral, Saptak Banerjee, Anamika Bose

10.1016/j.omton.2026.201250
View Publication

Induced pluripotent stem cell-derived dendritic cells potentiate the immunotherapeutic efficacy of interleukin 12-expressing oncolytic herpes virus

Satoru Taguchi, Hiroshi Fukuhara, Songjie Cai, Xiao-Kang Li, Akihiro Naito, Shigenori Kakutani, Yuta Takeshima, Jimpei Miyakawa, Haruki Kume, Tomoki Todo

10.1016/j.omton.2026.201252
View Publication

Frequently asked questions

How long does it take to publish?

Is a cover letter required?

A cover letter is required on institutional letterhead. It should explain the conceptual advance and relevance to readers and disclose information relevant to handling and evaluation of the paper, including related work, time constraints, competition, and any conflicts of interest.

Reformat to Molecular Therapy Oncology using Livewrite Premium

What are the publication costs?

Open access fee: $3,120 for members and $3,900 for non-members, plus VAT where applicable.

Reformat to Molecular Therapy Oncology using Livewrite Premium

Research Topics

CAR-T cell therapy research Virus-based gene therapy research Immunotherapy and Immune Responses Immune Cell Function and Interaction Cancer Research and Treatments Viral Infectious Diseases and Gene Expression in Insects Cancer Immunotherapy and Biomarkers Monoclonal and Polyclonal Antibodies Research RNA Interference and Gene Delivery CRISPR and Genetic Engineering Glioma Diagnosis and Treatment Nanowire Synthesis and Applications interferon and immune responses Ferroptosis and cancer prognosis Immune cells in cancer Animal Virus Infections Studies Neuroblastoma Research and Treatments Cancer Mechanisms and Therapy T-cell and B-cell Immunology Viral gastroenteritis research and epidemiology Ubiquitin and proteasome pathways Cell death mechanisms and regulation PARP inhibition in cancer therapy MicroRNA in disease regulation Pancreatic and Hepatic Oncology Research

Related Journals

Br
Breast Elsevier BV
JO
Journal Of Experimental & Clinical Cancer Research BioMed Central
TI
Trends In Cancer Elsevier BV
JO
Jnci-journal Of The National Cancer Institute Oxford University Press
IJ
International Journal Of Radiation Oncology Biology Physics Elsevier BV
IJ
International Journal Of Gynecological Cancer BMJ